Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…
PHILADELPHIA — The members of the American Association for Cancer Research (AACR) have elected José Baselga, M.D., Ph.D., physician-in-chief at Memorial Sloan Kettering Cancer Center in New York, N.Y., as their president-elect for 2014-2015. Baselga is an internationally recognized physician-scientist whose research focuses on the clinical development of novel molecularly targeted agents for the treatment of cancer, particularly breast cancer.
An international study published in The New England Journal of Medicine, in which the Vall d’Hebron University Hospital and Vall d´Hebron Institute of Oncology (VHIO) have participated, shows that administering bevacizumab in combination with chemotherapy in the first-line treatment of patients with recurrent and/or metastatic cervical cancer improves survival rates and reduces risk of death from this disease by 30%.
Comprised of AICR (now rebranded as Worldwide Cancer Research) donors, supporters, staff and AICR grant holders, some 15 individuals, including VHIO´s…
An interview with Ana Vivancos, Principal Investigator of VHIO´s Cancer Genomics Group “We are one of the few groups in…
Molecular Oncology 8 (2014) 1-8 News and views Towards individualized cancer therapy: Challenges and prospects Ezzie Hutchinson ABSTRACT At the…
Taking place on Monday 24 February 2014, 09:15 – 10:30, at the Hotel Alimara Barcelona, we are delighted to announce…
4th February, 2014, Strasbourg, France. A unique group of patient advocacy organisations, healthcare leaders (including two former health ministers and…
World Cancer Day is the singular initiative under which the UICC (Union for International Cancer Control), its members, partners, supporters…
Laura Soucek has been awarded an ERC Consolidator Grant for research into novel Myc inhibitor agents
• VHIO describes as many as four subgroups of HER2+ breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-Like) with…
Supported by the European Commission´s 7th Framework Programme of Research and Development, and coordinated by Catharine West, University of Manchester,…
Each year, in January, the Spanish periodical EL MUNDO publishes its selection of the 500 most influential Spanish citizens for that…
